摘要
目的:研究KIF20A对胶质瘤U87细胞系增殖、侵袭、迁移、凋亡及细胞周期分布的影响。方法:利用RNA干扰技术下调胶质瘤细胞系U87中KIF20A的表达。RT-qPCR和Western blot分别检测KIF20A在mRNA和蛋白水平上的表达。CCK-8实验检测U87细胞增殖能力的变化,Transwell实验检测U87细胞迁移及侵袭能力的变化,流式细胞术检测U87细胞凋亡及细胞周期的变化。结果:RT-qPCR和Western blot结果显示siRNA-KIF20A显著下调KIF20A的表达,CCK-8和Transwell实验显示下调KIF20A的表达显著抑制了U87细胞的增殖、迁移及侵袭能力,流式细胞术结果显示下调KIF20A的表达显著促进了U87细胞的凋亡,诱导细胞周期阻滞在G0/G1期。结论:下调KIF20A的表达抑制胶质母细胞瘤细胞的增殖、迁移及侵袭,促进胶质母细胞瘤细胞的凋亡并诱导细胞周期G0/G1期阻滞。
Objective:To study the effect of KIF20 A on proliferation,invasion,migration,apoptosis and cell cycle distribution of human glioma cell line U87.Methods:RNA interference technique was used to down-regulate the expression of KIF20 A in glioma cell line U87.RT-qPCR and Western blot were used to detect the expression of KIF20 A at mRNA and protein levels,respectively.The change of proliferation ability of U87 cells was detected by CCK-8 experiment.The change of migration and invasion ability of U87 cells was detected by Transwell experiment,and the change of apoptosis and cell cycle of U87 cells was detected by flow cytometry.Results:The results of RT-qPCR and Western blot showed that siRNA-KIF20 A significantly reduced the expression of KIF20 A.The CCK-8 and Transwell experiments showed that down-regulation of KIF20 A expression significantly inhibited the proliferation,migration and invasion of U87 cells.Flow cytometry showed that down-regulation of KIF20 A expression significantly promoted apoptosis of U87 cells and induced cell cycle arrest in G0/G1 phase.Conclusion:Down-regulation of KIF20 A expression inhibits proliferation,migration and invasion of glioblastoma cells,promotes apoptosis of glioblastoma cells and induces cell cycle G0/G1 phase arrest.
作者
刘纪营
吴妍妍
赵杰
张五松
靳振伟
陈健辉
郭新宾
Liu Jiying;Wu Yanyan;Zhao Jie;Zhang Wusong;Jin Zhenwei;Chen Jianhui;Guo Xinbin(Intervention Section,Xiangcheng Traditional Chinese Medicine Hospital,Henan Xiangcheng 466200,China;Department of Encephalopathy,Xiangcheng Traditional Chinese Medicine Hospital,Henan Xiangcheng 466200,China;Department of Neurology,Xiangcheng Traditional Chinese Medicine Hospital,Henan Xiangcheng 466200,China;Department of Neurointervention,the First Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450000,China)
出处
《现代肿瘤医学》
CAS
2020年第17期2943-2947,共5页
Journal of Modern Oncology
基金
河南省高等学校重点科研项目(编号:19A320034)。